
Managing Risks in Life Science Mergers and Acquisitions with Strategic Insurance
10/19/24 • 5 min
In this episode, we discuss the importance of integrating insurance considerations into the due diligence process during M&A transactions with Kenneth White.
In this episode, we discuss the importance of integrating insurance considerations into the due diligence process during M&A transactions with Kenneth White.
Previous Episode

Can a Pharmacist Override Your Doctor's Prescription?
We'll briefly discuss when a pharmacist might choose not to dispense medication, even with a valid doctor's order.
In a recent case, a doctor sued the Iowa Board of Pharmacy and the Iowa Board of Medicine when a pharmacy refused to fill a prescription for Ivermectin, a livestock drug sometimes used to treat parasites in people and allegedly COVID-19. This incident highlights a dilemma in the pharmacy world, especially post-pandemic. While pharmacists ensure the safety and appropriateness of medication, the debate around drugs like Ivermectin has spotlighted their autonomy and clinical judgment. Many states require pharmacists to act independently, determining the appropriateness of therapy in conjunction with doctors. This independent role can impact reimbursement, licensing, and job descriptions.
Switching gears, we also discuss pharmacists refusing to dispense birth control due to personal beliefs. A USA Today story exposed a scenario where a pharmacist refused to fill a birth control prescription, citing faith as the reason. Such actions raise questions about the extent to which pharmacists can exercise independent medical judgment.
Governmental authorities, like the Department of Health and Human Services, argue against pharmacists withholding medications based on personal beliefs, stating it creates barriers to essential healthcare. However, courts often decide these cases on a state-by-state basis.
As pharmacists, you're trusted to make decisions prioritizing patient care. These instances stress the traditional framework, urging a discussion on balancing professional discretion with medical guidelines. The ongoing cases and complex conversations invite deeper exploration into the ethics, laws, and evolving roles of pharmacists.
Next Episode

Are CROs Losing Relevance in the Age of DCTs?
In this episode, Isaac Rodriguez- Chavez and I discuss the impact of DCTs on sponsor relationships, CROs, and industry dynamics with the FDA.
We discuss,
1. How will DCTs impact sponsor relationships with CROs?
2. How do small CROs and sponsors adapt to emerging trends?
3. How do new trends impact industry relationships with the FDA?
4. Does DCT allows the FDA to advise sponsors?
5. What is the role of technology in DCTs?
6. How do DCTs reduce the cost of bringing drugs to the market?
7. What are the risks and advantages of DCTs?
8. What are the initial risks of DCTs?
9. Does the FDA even have jurisdiction over patient privacy?
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/darshantalks-podcast-403650/managing-risks-in-life-science-mergers-and-acquisitions-with-strategic-76705743"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to managing risks in life science mergers and acquisitions with strategic insurance on goodpods" style="width: 225px" /> </a>
Copy